Vericel commercializes advanced cell therapies and biologics for serious medical conditions in orthopedics and severe burns. Its best-known products include MACI, an autologous cultured chondrocyte implant for repairing certain knee cartilage defects, and Epicel, cultured epidermal autografts for patients with deep and extensive burns. The model combines specialized manufacturing of patient-specific or highly specialized living-cell products with a focused commercial organization. Customers are primarily orthopedic and burn specialists and the hospital systems that perform these procedures.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 52.6 | — | -11.3 | — |
| Q2 2025 | 63.2 | — | -0.6 | — |
| Q3 2025 | 67.5 | — | 5.1 | — |
| Q4 2025 | 92.9 | — | 23.2 | 23.9% |
| Q1 2026 | 68.4 | 30.1% | -6.3 | — |
| Q2 2026 | 77.5 | 22.5% | 2.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Happen, Inc. (HAPN), Xencor, Inc. (XNCR), PC Connection, Inc. (CNXN), Stoke Therapeutics, Inc. (STOK), Agios Pharmaceuticals, Inc. (AGIO), Fluence Energy, Inc. (FLNC)